Trials in Los Angeles, California
Here are the top 10 medical studies for breast cancer in Los Angeles, California
Popular Filters
Phase 3 Trials
Selective Estrogen Receptor Degrader (SERD)
Giredestrant + Everolimus for Advanced or Metastatic Breast Cancer
Recruiting2 awardsPhase 3
Los Angeles, California
This trial is testing if a combination of giredestrant and everolimus works better than other hormone treatments plus everolimus in patients with advanced breast cancer who have already tried other treatments. The drugs work by blocking estrogen receptors and a growth pathway in cancer cells. Everolimus has been shown to improve outcomes in breast cancer patients when combined with hormonal treatments.
Chemotherapy
Giredestrant + Phesgo for Breast Cancer
Recruiting2 awardsPhase 3
Los Angeles, California
This trial is testing whether a combination of two drugs is more effective than one drug for patients with advanced breast cancer. The drugs work by blocking signals that help cancer cells grow. The study focuses on patients whose cancer cannot be cured with surgery or other local treatments.
Monoclonal Antibodies
Sacituzumab Govitecan for Triple-Negative Breast Cancer
Recruiting4 awardsPhase 3
Torrance, California
This trial is testing a drug called sacituzumab govitecan-hziy, which targets and kills cancer cells. It focuses on patients with advanced triple-negative breast cancer who have limited treatment options. The drug works by attaching to cancer cells and releasing a substance that kills them. Sacituzumab govitecan-hziy is an FDA-approved treatment for metastatic triple-negative breast cancer, especially for patients who have already tried other treatments.
Antibody-Drug Conjugate
Sacituzumab Govitecan + Pembrolizumab for Triple-Negative Breast Cancer
Recruiting4 awardsPhase 3
Santa Barbara, California
This trial compares the effectiveness of a combination of two drugs, SG and pembrolizumab, in patients with advanced triple-negative breast cancer. SG targets and kills cancer cells with chemotherapy, while pembrolizumab helps the immune system attack the cancer. Pembrolizumab has been shown to improve survival in various cancers, including triple-negative breast cancer, when used alone or in combination with other treatments.
Anti-metabolites
Dato-DXd for Triple-negative Breast Cancer
Recruiting2 awardsPhase 3
Los Angeles, California
This trial is testing a new drug called Dato-DXd to see if it works better than current treatments for patients with a specific type of breast cancer that has come back or spread and cannot be treated with certain common therapies. The drug aims to target and kill cancer cells more effectively.
Selective Estrogen Receptor Downregulator (SERD)
Imlunestrant for Early Breast Cancer
Recruiting2 awardsPhase 3
Torrance, California
This trial is testing a new medication called imlunestrant to see if it works better than standard hormone treatments for certain breast cancer patients. The study focuses on patients with early-stage breast cancer that is estrogen receptor positive and HER2 negative, who have already been on hormone therapy for a period of time and are at high risk of their cancer returning. Imlunestrant works by blocking estrogen from helping cancer cells grow.
Trials With No Placebo
Monoclonal Antibodies
Ivermectin + Balstilimab for Breast Cancer
Recruiting2 awardsPhase 1 & 2
Los Angeles, California
This trial uses ivermectin and balstilimab to treat metastatic triple negative breast cancer. Ivermectin might stop new cancer growths, and balstilimab helps the immune system attack cancer cells. The goal is to shrink tumors and improve patient outcomes.
Small Molecule Inhibitor
LOXO-783 for Breast Cancer
Recruiting1 awardPhase 1
Santa Monica, California
This trial is testing LOXO-783, a new drug, to see if it is safe and effective for patients with breast cancer and other solid tumors that have a change in the PIK3CA gene. The drug works by blocking a gene that helps cancer cells grow.
Selective Estrogen Receptor Degrader (SERD)
Giredestrant + Everolimus for Advanced or Metastatic Breast Cancer
Recruiting2 awardsPhase 3
Los Angeles, California
This trial is testing if a combination of giredestrant and everolimus works better than other hormone treatments plus everolimus in patients with advanced breast cancer who have already tried other treatments. The drugs work by blocking estrogen receptors and a growth pathway in cancer cells. Everolimus has been shown to improve outcomes in breast cancer patients when combined with hormonal treatments.
Behavioral Intervention
Faith in Action! Church-based Navigation for Breast Cancer Screening
Recruiting1 award5 criteria
Los Angeles, California
This trial is testing a training curriculum to help laypeople in faith-based settings provide breast cancer screening navigation to Korean American women, to see if it increases adherence to breast cancer screening guidelines.
Chemotherapy
Giredestrant + Phesgo for Breast Cancer
Recruiting2 awardsPhase 3
Los Angeles, California
This trial is testing whether a combination of two drugs is more effective than one drug for patients with advanced breast cancer. The drugs work by blocking signals that help cancer cells grow. The study focuses on patients whose cancer cannot be cured with surgery or other local treatments.
CAR T-cell Therapy
LYL797 for Breast and Lung Cancer
Recruiting1 awardPhase 1
Santa Monica, California
This trial is testing a new treatment called LYL797, which uses modified immune cells to target and kill hard-to-treat breast and lung cancer cells. The study aims to find a safe dose and see how well it works in patients whose cancers have not responded to other treatments.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.